Beam Therapeutics Inc. Comprehensive Income
Beam Therapeutics Inc. (BEAM) reported Comprehensive Income of -$123.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-04
- Beam Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$123.80M.
- Beam Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$96.50M.
- Beam Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $244.62M.
- Beam Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$111.95M.
- Beam Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$79.56M.
- Beam Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$376.67M.
- Beam Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$129.49M.
- Beam Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$291.47M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$123.80M 10-Q · filed 2026-08-04 | -$220.30M 10-Q · filed 2026-08-04 | $24.32M derived: sum of 3 quarters · filed 2026-08-04 | -$87.63M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | -$96.50M 10-Q · filed 2026-05-07 | $148.12M derived: sum of 2 quarters · filed 2026-05-07 | $36.17M derived: sum of 3 quarters · filed 2026-05-07 | -$66.12M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $244.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $132.67M derived: sum of 2 quarters · filed 2026-02-24 | $30.38M derived: sum of 3 quarters · filed 2026-08-04 | -$79.56M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | -$111.95M 10-Q · filed 2025-11-04 | -$214.24M derived: sum of 2 quarters · filed 2026-08-04 | -$324.18M 10-Q · filed 2025-11-04 | -$414.52M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | -$102.29M 10-Q · filed 2026-08-04 | -$102.44M 10-Q · filed 2025-08-05 | -$211.14M 10-Q · filed 2026-08-04 | -$212.23M 10-Q · filed 2025-08-05 | -$302.57M derived: sum of 3 quarters · filed 2026-08-04 | -$396.37M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$108.85M 10-Q · filed 2026-05-07 | -$109.79M 10-Q · filed 2025-05-06 | -$200.28M derived: sum of 2 quarters · filed 2026-05-07 | -$294.08M derived: sum of 3 quarters · filed 2026-05-07 | -$385.32M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$91.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$185.23M derived: sum of 2 quarters · filed 2026-02-24 | -$276.47M derived: sum of 3 quarters · filed 2026-02-24 | -$376.67M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | -$93.80M 10-Q · filed 2025-11-04 | -$185.04M derived: sum of 2 quarters · filed 2025-11-04 | -$285.23M 10-Q · filed 2025-11-04 | -$139.81M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | -$91.24M 10-Q · filed 2025-08-05 | -$191.43M 10-Q · filed 2025-08-05 | -$46.01M derived: sum of 3 quarters · filed 2026-02-24 | -$142.11M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | -$100.19M 10-Q · filed 2025-05-06 | $45.23M derived: sum of 2 quarters · filed 2026-02-24 | -$50.87M derived: sum of 3 quarters · filed 2026-02-24 | -$134.89M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $145.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $49.33M derived: sum of 2 quarters · filed 2026-02-24 | -$34.70M derived: sum of 3 quarters · filed 2026-02-24 | -$129.49M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | -$96.10M 10-Q · filed 2024-11-05 | -$180.12M derived: sum of 2 quarters · filed 2024-11-05 | -$274.92M 10-Q · filed 2024-11-05 | -$311.02M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-06-30 | -$84.03M 10-Q · filed 2024-08-06 | -$178.82M 10-Q · filed 2024-08-06 | -$214.93M derived: sum of 3 quarters · filed 2025-02-25 | -$324.99M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-03-31 | -$94.80M 10-Q · filed 2024-05-07 | -$130.90M derived: sum of 2 quarters · filed 2025-02-25 | -$240.96M derived: sum of 3 quarters · filed 2025-02-25 | -$314.39M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2022-12-31 | -$36.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$146.16M derived: sum of 2 quarters · filed 2025-02-25 | -$219.59M derived: sum of 3 quarters · filed 2025-02-25 | -$291.47M 10-K · filed 2025-02-25 | ||
| 2022-09-30 | -$110.06M 10-Q · filed 2023-11-08 | -$183.49M derived: sum of 2 quarters · filed 2023-11-08 | -$255.36M 10-Q · filed 2023-11-08 | -$320.14M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | -$73.43M 10-Q · filed 2023-08-08 | -$145.30M 10-Q · filed 2023-08-08 | -$210.08M derived: sum of 3 quarters · filed 2024-02-27 | -$238.21M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | -$71.87M 10-Q · filed 2023-05-10 | -$136.65M derived: sum of 2 quarters · filed 2024-02-27 | -$164.78M derived: sum of 3 quarters · filed 2024-02-27 | -$240.98M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2021-12-31 | -$64.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$92.91M derived: sum of 2 quarters · filed 2024-02-27 | -$169.10M derived: sum of 3 quarters · filed 2024-02-27 | -$370.68M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | -$28.13M 10-Q · filed 2022-11-07 | -$104.33M derived: sum of 2 quarters · filed 2022-11-07 | -$305.90M 10-Q · filed 2022-11-07 | -$401.42M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | -$76.20M 10-Q · filed 2022-08-09 | -$277.77M 10-Q · filed 2022-08-09 | -$373.29M derived: sum of 3 quarters · filed 2023-02-28 | -$407.87M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | -$201.57M 10-Q · filed 2022-05-09 | -$297.09M derived: sum of 2 quarters · filed 2023-02-28 | -$331.67M derived: sum of 3 quarters · filed 2023-02-28 | -$365.37M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | -$95.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$130.10M derived: sum of 2 quarters · filed 2023-02-28 | -$163.80M derived: sum of 3 quarters · filed 2023-02-28 | -$194.62M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | -$34.58M 10-Q · filed 2021-11-08 | -$68.28M derived: sum of 2 quarters · filed 2021-11-08 | -$99.10M 10-Q · filed 2021-11-08 | -$126.98M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | -$33.70M 10-Q · filed 2021-08-10 | -$64.52M 10-Q · filed 2021-08-10 | -$92.40M derived: sum of 3 quarters · filed 2022-02-28 | -$111.44M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | -$30.82M 10-Q · filed 2021-05-11 | -$58.70M derived: sum of 2 quarters · filed 2022-02-28 | -$77.74M derived: sum of 3 quarters · filed 2022-02-28 | -$95.52M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | -$27.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$46.92M derived: sum of 2 quarters · filed 2022-02-28 | -$64.70M derived: sum of 3 quarters · filed 2022-02-28 | -$78.31M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$19.04M 10-Q · filed 2020-11-10 | -$36.82M derived: sum of 2 quarters · filed 2020-11-10 | -$50.43M 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | -$17.78M 10-Q · filed 2020-08-12 | -$31.39M 10-Q · filed 2020-08-12 | ||||
| 2019-03-31 | -$13.61M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |